Table 2 Summary of the adverse events that occurred in the two treatment groups (safety population)
Adverse event | Pertuzumab group [cases (%)] n = 83 | Control group [cases (%)]n = 80 |
|---|---|---|
All-grade AEs | 83 (100.0) | 78 (97.5) |
 Grade 3–5 AEs | 67 (80.7) | 52 (65.0) |
 Serious AEs | 17 (20.5) | 12 (15.0) |
 AEs leading to treatment discontinuation | 7 (8.4) | 5 (6.3) |
 AEs with fatal outcome | 3 (3.6) | 6 (7.5) |
AEs leading to study withdrawal | 1 (1.2) | 2 (2.5) |